Variant Philadelphia translocations with different breakpoints in six chronic myeloid leukemia patients. 2011

Dilhan Kuru, and Yelda Tarkan Argüden, and Muhlis Cem Ar, and Ayşe Çırakoğlu, and Şeniz Öngören, and Şükriye Yılmaz, and Ahmet Emre Eşkazan, and Ayhan Deviren, and Teoman Soysal, and Seniha Hacıhanefioğlu, and Birsen Ülkü
Department of Medical Biology, Cerrahpaşa Faculty of Medicine, İstanbul University, İstanbul, Turkey Phone: +90 212 414 30 34 E-mail: dilhank@istanbul.edu.tr.

OBJECTIVE The Philadelphia (Ph) chromosome, consisting of the t(9;22)(q34;q11) translocation, is observed in ~90% of patients with chronic myeloid leukemia (CML). Variant Ph translocations are observed in 5%-10% of CML patients. In variant translocations 3 and possibly more chromosomes are involved. Herein we report 6 CML patients with variant Ph translocations. METHODS Bone marrow samples were examined using conventional cytogenetic meth ods. Fluorescence in situ hybridization (FISH) with whole-chromosome paints and BCR-ABL 1D probes were used to confirm and/or complement the findings, and identify rearrangements beyond the resolution of conventional cytogenetic methods. RESULTS Variant Ph translocations in the 6 patients were as follows: t(7;22)(p22;q11), t(9;22;15)(q34;q11;q22), t(15;22)(p11;q11), t(1;9;22;3)(q24;q34;q11;q21), t(12;22)(p13;q11), and t(4;8;9;22)(q11;q13;q34;q11). CONCLUSIONS Among the patients, 3 had simple and 3 had complex variant Ph translocations. Two of the presented cases had variant Ph chromosomes not previously described, 1 of which had a new complex Ph translocation involving chromosomes 1, 3, 9, 22, and t(1;9;22;3)(q24;q34;q11;q21) apart from a clone with a classical Ph, and the other case had variant Ph translocation with chromosomes 4, 8, 9, and 22, and t(4;8;9;22)(q11;q13;q34;q11) full complex translocation. Number of studies reported that some patients with variant Ph translocation were poor responders to imatinib. All of our patients with variant Ph translocations had suboptimal responses to imatinib, denoting a poor prognosis also. Variant Ph translocations may be important as they are associated with prognosis and therapy for CML patients.

UI MeSH Term Description Entries

Related Publications

Dilhan Kuru, and Yelda Tarkan Argüden, and Muhlis Cem Ar, and Ayşe Çırakoğlu, and Şeniz Öngören, and Şükriye Yılmaz, and Ahmet Emre Eşkazan, and Ayhan Deviren, and Teoman Soysal, and Seniha Hacıhanefioğlu, and Birsen Ülkü
October 1986, Blut,
Dilhan Kuru, and Yelda Tarkan Argüden, and Muhlis Cem Ar, and Ayşe Çırakoğlu, and Şeniz Öngören, and Şükriye Yılmaz, and Ahmet Emre Eşkazan, and Ayhan Deviren, and Teoman Soysal, and Seniha Hacıhanefioğlu, and Birsen Ülkü
February 1989, Cancer genetics and cytogenetics,
Dilhan Kuru, and Yelda Tarkan Argüden, and Muhlis Cem Ar, and Ayşe Çırakoğlu, and Şeniz Öngören, and Şükriye Yılmaz, and Ahmet Emre Eşkazan, and Ayhan Deviren, and Teoman Soysal, and Seniha Hacıhanefioğlu, and Birsen Ülkü
January 1987, Cytogenetics and cell genetics,
Dilhan Kuru, and Yelda Tarkan Argüden, and Muhlis Cem Ar, and Ayşe Çırakoğlu, and Şeniz Öngören, and Şükriye Yılmaz, and Ahmet Emre Eşkazan, and Ayhan Deviren, and Teoman Soysal, and Seniha Hacıhanefioğlu, and Birsen Ülkü
December 1990, Cancer letters,
Dilhan Kuru, and Yelda Tarkan Argüden, and Muhlis Cem Ar, and Ayşe Çırakoğlu, and Şeniz Öngören, and Şükriye Yılmaz, and Ahmet Emre Eşkazan, and Ayhan Deviren, and Teoman Soysal, and Seniha Hacıhanefioğlu, and Birsen Ülkü
May 1993, Cancer genetics and cytogenetics,
Dilhan Kuru, and Yelda Tarkan Argüden, and Muhlis Cem Ar, and Ayşe Çırakoğlu, and Şeniz Öngören, and Şükriye Yılmaz, and Ahmet Emre Eşkazan, and Ayhan Deviren, and Teoman Soysal, and Seniha Hacıhanefioğlu, and Birsen Ülkü
October 1986, Cancer genetics and cytogenetics,
Dilhan Kuru, and Yelda Tarkan Argüden, and Muhlis Cem Ar, and Ayşe Çırakoğlu, and Şeniz Öngören, and Şükriye Yılmaz, and Ahmet Emre Eşkazan, and Ayhan Deviren, and Teoman Soysal, and Seniha Hacıhanefioğlu, and Birsen Ülkü
January 1986, Nouvelle revue francaise d'hematologie,
Dilhan Kuru, and Yelda Tarkan Argüden, and Muhlis Cem Ar, and Ayşe Çırakoğlu, and Şeniz Öngören, and Şükriye Yılmaz, and Ahmet Emre Eşkazan, and Ayhan Deviren, and Teoman Soysal, and Seniha Hacıhanefioğlu, and Birsen Ülkü
October 1989, Cancer genetics and cytogenetics,
Dilhan Kuru, and Yelda Tarkan Argüden, and Muhlis Cem Ar, and Ayşe Çırakoğlu, and Şeniz Öngören, and Şükriye Yılmaz, and Ahmet Emre Eşkazan, and Ayhan Deviren, and Teoman Soysal, and Seniha Hacıhanefioğlu, and Birsen Ülkü
January 2015, Revista brasileira de hematologia e hemoterapia,
Dilhan Kuru, and Yelda Tarkan Argüden, and Muhlis Cem Ar, and Ayşe Çırakoğlu, and Şeniz Öngören, and Şükriye Yılmaz, and Ahmet Emre Eşkazan, and Ayhan Deviren, and Teoman Soysal, and Seniha Hacıhanefioğlu, and Birsen Ülkü
January 2015, Journal of cancer research and therapeutics,
Copied contents to your clipboard!